Indian pharmaceutical company Wockhardt has announced a significant strategic shift in its U.S. operations, marking a new chapter focused on innovation-led growth and portfolio rationalization. The company is phasing out its conventional U.S. generics business to channel efforts into high-value specialty products and innovative therapies.
As part of this transformation, Wockhardt has wound down manufacturing activities at its Morton Grove facility near Chicago. The decision follows a broader internal review aimed at optimizing operational efficiency, capital deployment, and market focus. The company confirmed that it will now concentrate on leveraging third-party partnerships and its proprietary research to advance specialty products with a stronger margin profile.
According to Wockhardt’s statement, this move is intended to realign the organization with its long-term vision of becoming a global leader in innovation-based healthcare. The company emphasized that the U.S. remains a key strategic market, but its future approach will focus on differentiated offerings rather than volume-driven generics.
This realignment will also help Wockhardt achieve significant cost savings, improve profitability, and support its global innovation agenda, especially in areas such as anti-infectives, biotechnology, and novel drug delivery systems.
The company reassured stakeholders that existing obligations and product availability in the U.S. will be maintained through a streamlined, third-party manufacturing strategy, ensuring business continuity during the transition.
